Research programme: neurological disorders kinase inhibitors - Arrien Pharmaceuticals

Drug Profile

Research programme: neurological disorders kinase inhibitors - Arrien Pharmaceuticals

Alternative Names: ARN-1104; ORS 1006; ORS 1104

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator Oros Pharmaceuticals
  • Developer Arrien Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action DYRK kinase inhibitors; LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Preclinical Parkinson's disease
  • Discontinued Alzheimer's disease; Down syndrome

Most Recent Events

  • 09 Sep 2016 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 09 Sep 2016 Discontinued - Preclinical for Down syndrome in USA (PO)
  • 09 Sep 2016 Preclinical development is ongoing in USA (Arrien Pharmaceuticals Pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top